- Pancreatic adenocarcinoma is the most common type; it rarely causes early symptoms, so it is usually found late.
- About 90% of cases are acquired (lifestyle/environment); only ~10% are inherited.
- Modifiable risks include sugar, smoking, alcohol, excess weight, pesticides and cadmium.
- Treatment (surgery, radiotherapy, chemotherapy) depends on stage; immune support is studied as an adjunct alongside it.
What is pancreatic cancer?
Pancreatic cancer is a tumour found in any part of the pancreas. Cancer begins when cells start to multiply uncontrollably. Pancreatic adenocarcinoma is the most common type. The pancreas produces hormones and enzymes that help digest food and, among other functions, regulate blood sugar levels.

Symptoms
Pancreatic cancer often shows no symptoms until it reaches a later stage — so there are no reliable early signs. The most common symptoms of established cancer are:
- Loss of appetite
- Weight loss
- Abdominal or back pain
- Blood clots
- Yellowing of the eyes (jaundice)
- Depression
As the cancer spreads, symptoms become more pronounced and new ones may appear.
Did I inherit it?
Only up to 1 in 10 pancreatic cancer cases may be inherited. The other 90% are acquired — mutations that happen during life, not inherited ones. These DNA mutations are not passed from parents to children.1
Why do we get it?
Causes within your control:
- Sugar, sweetened drinks and sweets2
- Smoking3
- Alcohol4
- Pesticides5
- Excess weight3
- Environmental chemicals6
- Cadmium7
Stages
Once pancreatic cancer is found, further tests assess how far it has spread. Based on the results, the oncologist assigns a stage:
- Stage 1: the cancer is confined to the pancreas.
- Stage 2: spread to nearby tissues or lymph nodes.
- Stage 3: spread to major blood vessels and lymph nodes.
- Stage 4: spread to other organs, such as the liver.
Life expectancy with pancreatic cancer depends heavily on spread, the treatment chosen, and the patient's condition.
Treatment
Treatment and survival depend on the stage. The goal is to destroy cancer cells and prevent the disease from spreading. The most common complications during treatment are weight loss, constipation, abdominal pain and liver failure.
Surgery: the stage and location determine whether surgery is performed. Surgery can remove the primary tumour, but it will not remove cancer that has spread elsewhere — so it may be unsuitable for people with advanced-stage pancreatic cancer. Radiotherapy: when the cancer has spread beyond the pancreas, radiotherapy may be prescribed, using X-rays and other radiation to destroy cancer cells. Chemotherapy: in some cases the oncologist may combine chemotherapy with other treatments.
What else can I do in the fight against pancreatic cancer?
If you want to help your body heal, reduce inflammation, balance your diet and strengthen the immune system's ability to recognise and destroy altered cells, relying on chemotherapy, surgery or radiotherapy alone will not be enough (though do not avoid them — with prevention you are already late). You will help yourself considerably by doing the following:
- Lentinan supplements are used at all stages of cancer treatment. Lentinan improves the effectiveness of conventional treatment, reduces side effects, and improves quality of life. These are active compounds extracted from medicinal mushrooms, widely used in the East (Japan), because they are powerful immunomodulators that prompt the immune system to detect and destroy cancer cells. The shortest recommended course is 3 months — the longer it is taken, the better the results.
- Breathing exercises — look into the Wim Hof method.
- Exercise (do not underestimate it!).
- And be sure to read about what to eat after chemotherapy.
Pancreatic cancer is hard to catch early. Concentrated mushroom polysaccharides are studied for their role in supporting NK-cell and macrophage activity alongside conventional treatment.
Lentinan AXT by Zenius Labs™ →Pancreatic cancer often causes no symptoms until a later stage, so there are no reliable early signs. Common symptoms of established disease include loss of appetite, weight loss, abdominal or back pain, blood clots, jaundice (yellowing of the eyes), and depression.
Only up to 1 in 10 cases may be inherited. The other 90% are acquired — DNA mutations that happen during life and are not passed from parents to children.
Yes. Chemotherapy and radiotherapy suppress the immune system. Concentrated mushroom-polysaccharide extracts are studied for their role in helping activate natural killer cells and macrophages. It is important to choose a concentrated multi-extract formula such as Lentinan AXT by Zenius Labs™ rather than simple powders.
Factors within your control include sugar and sweetened drinks, smoking, alcohol, excess weight, pesticides, environmental chemicals and cadmium. Genetics accounts for only about 10% of cases.
- Heavy Drinking Linked to Pancreatic Cancer. WebMD
- Environment and Health Research Newsletter. European Commission
- Common Chemicals Linked to Pancreatic Cancer. WebMD
- Risk of pancreatic cancer and occupational exposures in Spain. Cancer Epidemiology
- Capula M et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022. PubMed
- Kim G nab-Paclitaxel for the treatment of pancreatic cancer. Cancer management and research. 2017. PubMed
- Zhang Y et al. Immune Therapy in Pancreatic Cancer: Now and the Future?. Reviews on recent clinical trials. 2015. PubMed
- Das S et al. Harnessing the Immune System in Pancreatic Cancer. Current treatment options in oncology. 2018. PubMed
- Carpenter ES et al. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cancer research. 2020. PubMed
- Tang M et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of controlled release : official journal of the Controlled Release Society. 2019. PubMed
- Zheng R et al. Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. Oncology reports. 2026. PubMed
- Jiang S et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. Journal of experimental & clinical cancer research : CR. 2023. PubMed
- Goetze TO et al. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology. 2024. PubMed
- Byrne JD et al. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer chemotherapy and pharmacology. 2018. PubMed
- Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. 2016. PubMed
- Tran NH et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International journal of radiation oncology, biology, physics. 2020. PubMed
- Lee JH et al. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells. 2021. PubMed
- Zhang Y et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. International immunopharmacology. 2008. PubMed
- Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
- Bossi P et al. The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021. PubMed
- Luo L et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano today. 2024. PubMed
- Mortezaee K Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. Journal of biochemical and molecular toxicology. 2021. PubMed
- Liu X et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science translational medicine. 2024. PubMed
- Datta J et al. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer. Gastroenterology. 2022. PubMed
- Lin HJ et al. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Cancers. 2023. PubMed
- Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
- Liu Y et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell death and differentiation. 2025. PubMed
- Zhou J et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer letters. 2023. PubMed
- Deng Y et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature communications. 2021. PubMed
- Zhou W et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021. PubMed
- Mukherji R et al. The Role of Immunotherapy in Pancreatic Cancer. Current oncology (Toronto, Ont.). 2022. PubMed
- Feng M et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer letters. 2017. PubMed
- Jolly G et al. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers. 2023. PubMed
- Bangolo AI et al. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights. World journal of gastroenterology. 2023. PubMed
- Halle-Smith JM et al. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?. Cancers. 2023. PubMed
- Li P et al. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Cancer letters. 2024. PubMed
- Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
- Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
- Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
- Zhang P et al. A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. International journal of nanomedicine. 2018. PubMed
- Shimizu K et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterology. 2009. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
- Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
- Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed